Evaluating the Impact of Hepatic or Renal Impairment on Tanimilast (CHF6001) Pharmacokinetics: Two Open‐Label, Parallel‐Group, Single‐Center Studies
ABSTRACT Tanimilast is an inhaled phosphodiesterase‐4 inhibitor in development for chronic obstructive pulmonary disease and asthma. We conducted two studies to evaluate tanimilast pharmacokinetics, one in subjects with mild, moderate, or severe hepatic impairment and matched healthy controls, and o...
Gorde:
| Egile Nagusiak: | , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Wiley
2025-05-01
|
| Saila: | Clinical and Translational Science |
| Gaiak: | |
| Sarrera elektronikoa: | https://doi.org/10.1111/cts.70261 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|